Title | Deficiency of galactosyl-ceramidase in adult oligodendrocytes worsens disease severity during chronic experimental allergic encephalomyelitis. |
Publication Type | Journal Article |
Year of Publication | 2024 |
Authors | Saldivia N, Heller G, Zelada D, Whitehair J, Venkat N, Konjeti A, Savitzky R, Samano S, Simchuk D, van Breemen R, Givogri MI, Bongarzone ER |
Journal | Mol Ther |
Volume | 32 |
Issue | 9 |
Pagination | 3163-3176 |
Date Published | 2024 Sep 04 |
ISSN | 1525-0024 |
Keywords | Animals, Chronic Disease, Disease Models, Animal, Encephalomyelitis, Autoimmune, Experimental, Galactosylceramidase, Lysosomes, Mice, Mice, Knockout, Myelin Sheath, Oligodendroglia, Severity of Illness Index |
Abstract | Galactosyl-ceramidase (GALC) is a ubiquitous lysosomal enzyme crucial for the correct myelination of the mammalian nervous system during early postnatal development. However, the physiological consequence of GALC deficiency in the adult brain remains unknown. In this study, we found that mice with conditional ablation of GALC activity in post-myelinating oligodendrocytes were lethally sensitized when challenged with chronic experimental allergic encephalomyelitis (EAE), in contrast with the non-lethal dysmyelination observed in Galc-ablated mice without the EAE challenge. Mechanistically, we found strong inflammatory demyelination without remyelination and an impaired fusion of lysosomes and autophagosomes with accumulation of myelin debris after a transcription factor EB-dependent increase in the lysosomal autophagosome flux. These results indicate that the physiological impact of GALC deficiency is highly influenced by the cell context (oligodendroglial vs. global expression), the presence of inflammation, and the developmental time when it happens (pre-myelination vs. post-myelination). We conclude that Galc expression in adult oligodendrocytes is crucial for the maintenance of adult central myelin and to decrease vulnerability to additional demyelinating insults. |
DOI | 10.1016/j.ymthe.2024.06.035 |
Alternate Journal | Mol Ther |
PubMed ID | 38937968 |